<DOC>
	<DOC>NCT00652223</DOC>
	<brief_summary>The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.</brief_summary>
	<brief_title>Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<criteria>Mild to moderate perennial allergic rhinoconjunctivitis due to sensitization against house dust mites Mild asthma Females only if nonreproductive or agree to practice an effective and accepted method of contraception Relevant cardiovascular, renal, pulmonary or endocrine disease History of autoimmune disease Severe allergies History of active infectious disease Current diagnosis or history of malignancy Relevant neurological or psychiatric disorder Pregnancy or lactation History of alcohol abuse or other recreational drugs Use of an investigational drug within three month before enrolment Blood donation within 30 days before enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>